It does this by inducing the expression of drug resistance genes downstream of PXR, such as cyp3a4 or abcb1 (ATP-binding cassette, sub-family B, member 1), and through a similar negative feedback mechanism that induces resistance of HCC cells to sorafenib itself. Here, CYP3A4 is linked to hepatocellular carcinoma.